NCT04110886View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetics of HSK21542 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

July 2, 2020

Primary Completion Date

December 8, 2020

Study Completion Date

January 5, 2021

Conditions
Postoperative PainChronic Pain
Interventions
DRUG

HSK21542

Single dose, injection, starting dose of 0.2ug escalating up to 20ug

DRUG

Placebo

Single dose, injection matching placebo

Trial Locations (1)

Unknown

CMAX Clinical Research Pty Ltd, Adelaide

All Listed Sponsors
lead

Sichuan Haisco Pharmaceutical Group Co., Ltd

INDUSTRY

NCT04110886 - Safety, Tolerability, and Pharmacokinetics of HSK21542 in Healthy Volunteers | Biotech Hunter | Biotech Hunter